Patent · US Active

Selective histone deacetylase inhibitors for the treatment of human disease

US11034667B2 · kind B2 · utility

0Cited by
78References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 9, 2018
Grant dateJun 15, 2021
Priority date
Expiry dateJan 9, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K45/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.